Voyager Therapeutics, Inc. (NASDAQ:VYGR) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 1,346,882 shares, an increase of 44.9% from the October 13th total of 929,333 shares. Currently, 10.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 413,483 shares, the short-interest ratio is currently 3.3 days.

In other news, insider Bernard Ravina sold 16,470 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.87, for a total value of $211,968.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders sold 38,430 shares of company stock valued at $562,890. 8.00% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in VYGR. Wells Fargo & Company MN increased its stake in Voyager Therapeutics by 312.8% in the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after acquiring an additional 285,806 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Voyager Therapeutics during the third quarter worth $5,155,000. DAFNA Capital Management LLC grew its stake in shares of Voyager Therapeutics by 187.2% during the second quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after buying an additional 133,488 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Voyager Therapeutics during the third quarter worth $2,695,000. Finally, Mckinley Capital Management LLC Delaware bought a new stake in shares of Voyager Therapeutics during the third quarter worth $1,412,000. 40.93% of the stock is currently owned by institutional investors and hedge funds.

VYGR has been the subject of a number of analyst reports. Wedbush reiterated a “positive” rating and issued a $31.00 price target (down from $36.00) on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Canaccord Genuity initiated coverage on shares of Voyager Therapeutics in a research report on Friday, October 27th. They issued a “buy” rating and a $35.00 price target for the company. Zacks Investment Research downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Cowen and Company reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Finally, ValuEngine cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $26.75.

Voyager Therapeutics (NASDAQ:VYGR) opened at $12.95 on Friday. Voyager Therapeutics has a one year low of $8.10 and a one year high of $25.99.

COPYRIGHT VIOLATION WARNING: “Voyager Therapeutics, Inc. (VYGR) Short Interest Update” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/18/voyager-therapeutics-inc-vygr-short-interest-update.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.